Why Moderna, Inc.’s (MRNA) Stock Is Down 5.41%
As of Tuesday, November 10, Moderna, Inc.’s MRNA share price has dipped by 5.41%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Commentary & Analysis
Why Moderna, Inc.’s (MRNA) Stock Is Up 8.27%
As of Monday, November 09, Moderna, Inc.’s MRNA share price has surged by 8.27%, which has investors questioning if this is right time to sell.Jenna Brashear
What You Need to Know About Moderna, Inc.'s Q4 Earnings
Moderna, Inc.'s fiscal Q4 earnings report was released on Friday, November 06. Let's dive in to see if (MRNA) missed or beat analyst's expectations.Rosalio Madrigal
Why Moderna, Inc.’s (MRNA) Stock Is Up 7.83%
As of Friday, November 06, Moderna, Inc.’s MRNA share price has surged by 7.83%, which has investors questioning if this is right time to sell.Tudor Pop
Why Moderna, Inc.’s (MRNA) Stock Is Up 9.40%
As of Wednesday, November 04, Moderna, Inc.’s MRNA share price has surged by 9.40%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | MRNA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $93,609.1 | $218.8 | 96% |
|
| Shares Out (Mil) | 430.0 | 55.0 | 87% |
|
| Institutional Ownership | 92.3% | 92.8% | 61% |
|
| Float (Mil) | 377.4 | 42.0 | 82% |
|
| Beta | 1.17 | 0.96 | 69% |
|
| Avg Daily Volume (000s) | 10,815 | 546 | 96% |
|
| Price Change (52-week) |
776.0% | 44.0% | 100% |
|
| Growth | MRNA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 19.3% | 13.6% | 80% |
|
| Net Income (5yr) | (30.5%) | (10.3%) | 13% |
|
| EPS (5yr) | (29.9%) | 15.8% | 8 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (22.8%) | (15.7%) | 29% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 16 | 16 | |
| Current EPS | ($2.157) | ($7.272) | ($4.129) | |
| Month Ago EPS | ($1.741) | ($8.398) | ($4.438) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($1.924) | ($8.639) | ($4.843) | |
| Year/Year Chg | (669.1%) | 0.2% | (63.4%) | |
| Financials | MRNA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2,525 | $41 | 63% |
|
| Net Income (TTM) (Mil) | ($2,789) | ($43) | 0% |
|
| EPS (TTM) | ($7.034) | ($1.500) | 6% |
|
| Operating Cash Flow (TTM) (Mil) | ($1,785) | ($35) | 1% |
|
| Net Cash Flow (TTM) (Mil) | $62 | $-0 | 72% |
|
| Long-Term Debt (Q1) (Mil) | $4,179 | $4 | 83% |
|
| Enterprise Value (Q1) (Mil) | $99,104 | $157 | 96% |
|
| Valuation | MRNA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 13.67 | 2.08 | 94% |
|
| P/E | na | 17.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | MRNA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (42.0%) | 68.1% | 2% |
|
| Net Margin | (110.5%) | (50.8%) | 7% |
|
| ROA | (21.8%) | (47.4%) | 19% |
|
| ROE | (34.5%) | (52.5%) | 19% |
|
| Liabilities to Assets | 49.2% | 29.7% | 41% |
|
| F-Score | 4 | 3 | 34% |
|
Moderna, Inc. did not pass any screens on 11/12/2026.
